Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
01/2003
01/16/2003US20030013674 Gene therapy; in situ supplying of genes; nucleic acid complex
01/16/2003US20030013671 Genomic DNA library
01/16/2003US20030013669 Method of treating HIV infection and related secondary infections thereof
01/16/2003US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis
01/16/2003US20030013662 Novel polyketide derivatives and recombinant methods for making same
01/16/2003US20030013651 Stimulation of osteogenesis using rank ligand fusion proteins
01/16/2003US20030013644 Complexing; therapy for genetic defects
01/16/2003US20030013636 Prevent biosynthesis of galactoside
01/16/2003US20030013197 Generation of adenovirus associated vector cultures; obtain cells, infect with expression vector, express vector and recover viral particles
01/16/2003US20030013196 Expression vector for use as tools in genetic engineering and gene therapy
01/16/2003US20030013195 Virus envelope vector for gene transfer
01/16/2003US20030013190 Altered strain of the modified vaccinia virus ankara (mva)
01/16/2003US20030013189 Noninvasive transfer of pharmocological agent into bloodstream; administer adenovirus to human, monitor response to pharmacological agent in lungs
01/16/2003US20030013182 Isolation of gene expressing preferential polypeptide; obtain nucleotide sequences, incubate with probes, monitor gene expression isolatea gene from microorganism
01/16/2003US20030013181 Novel nucleic acids and polypeptides related to a farnesyl-directed endopeptidase
01/16/2003US20030013180 Pullulanase for use in saccharfication of stsrches
01/16/2003US20030013179 Enzymatic polypeptide for use in the treatment of lysosomal storage disorders
01/16/2003US20030013177 Polynucleotides encoding insect glutaminyl cyclase and uses thereof
01/16/2003US20030013176 Enzymatic crystal of preferential protein for use in evaluating inhibitor binding activity
01/16/2003US20030013175 Enzymatic polypetide for use in modifying carbohydrates
01/16/2003US20030013174 Genes for lysine biosynthetic system derived from thermophilic bacteria
01/16/2003US20030013171 Nucleotide sequences coding polypeptide for use in treatment or prevention of immune system disorders
01/16/2003US20030013170 Inhibitors of receptor activator of NF-kappaB and uses thereof
01/16/2003US20030013168 Peptide for use in human therapeutics and diagnostic compositions
01/16/2003US20030013158 Delta subunit of human GABAA receptor
01/16/2003US20030013157 Culturing cells which generate preferential immunoglobulins; obtain cell, transform cell, recover cell expressing preferential immunoglobulin, isolate immunoglobulin
01/16/2003US20030013149 Quantitative analysis
01/16/2003US20030013144 Detection of modulator of cancer activity; obtain sample containing biopolymers, incubate with modulator, monitor cellular response
01/16/2003US20030013143 Methods for identifying vasoprotective agents
01/16/2003US20030013139 Transgenic cells for use as diagnostic tools in genetic engineering
01/16/2003US20030013137 Detection of G protein-coupled receptor activity in cell; obtain cell, incubate with moulator, monitor receptor activity, generate image, determine position of bninding site
01/16/2003US20030013133 Detection of a biological target
01/16/2003US20030013122 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
01/16/2003US20030013108 Novel RIP3 associated cell cycle proteins, compositions and methods of use
01/16/2003US20030013104 Monitoring the effectiveness of bactericide; obtain resistant bacterial cell, incubate with bactericide, monitor bacterial response to bactericide
01/16/2003US20030013102 D-hydantoinase from Ochrobactrum anthropi
01/16/2003US20030013097 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
01/16/2003US20030013095 Nuclcic acid enzyme for use in the prevention and treatment of infections and cancer
01/16/2003US20030013091 Methods for detection and quantification of analytes in complex mixtures
01/16/2003US20030013087 Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
01/16/2003US20030013085 Production of replicative hepatitis C virus
01/16/2003US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
01/16/2003US20030013079 Generation of preferential viral particle; obtain cells, transform with expresion vector, culture cell, recover viral particle
01/16/2003US20030013078 Expression vector for use in the prevention and treatment of vial infection
01/16/2003US20030013077 Binding to monoclonal antibodies; detection of Kaposi's sarcoma
01/16/2003US20030013076 Viral vector for use as tool in genetic engineering and human therapeutics
01/16/2003US20030012813 Cationic lipid with a lipophilic group derived from cholesterol; an amide or carbamate linker bond; an alkylene spacer arm; and a cationic primary, secondary, tertiary or quaternary amino group. facilitating nucleic acid transfer
01/16/2003US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
01/16/2003US20030012790 Especially bispecific molecules comprising an IFN- gamma inhibitor and a further specificity to a target involved in the initiation or development of IBD, including ulcerative colitis and Crohn's disease.
01/16/2003US20030012787 Especially for ulcerative colitis and Crohn's disease.
01/16/2003US20030012782 Method and composition for altering a T cell mediated pathology
01/16/2003US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
01/16/2003US20030012777 Polymer conjugates of proteinases
01/16/2003US20030012776 A nucleic acid sequence which encodes RIAZ protein; abolishing drug resistance in cancer cells; drug development assay; diagnosing and treating cancer; gene therapy; prediction of chemosensitivity in cancer patients
01/16/2003US20030012770 Recombinant p53 adenovirus methods and compositions
01/16/2003US20030012769 Wherein a part or all of a regulatory element of the U3 region of the 5' LTR is replaced by another regulatory element, operable in a mammalian cell, which is not endogenous to said lentivirus.
01/16/2003US20030012767 Tissue-specific taanscriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector.
01/16/2003US20030012766 Orally-administered interferon-tau compositions and methods
01/16/2003US20030010715 Use of cationic exchange chromatography on solid matrix carried out at basic pH
01/16/2003US20030010712 Process for biochemical treatment of waste water using nano materials
01/16/2003CA2812821A1 Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences
01/16/2003CA2812799A1 Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences
01/16/2003CA2798555A1 Methods for detection and quantification of analytes in complex mixtures
01/16/2003CA2785699A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
01/16/2003CA2488550A1 A bioprocess for producing uniform embryoid bodies from embryonic stem cells in a high density bioreactor
01/16/2003CA2467006A1 Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses
01/16/2003CA2462951A1 Isolation and purification of plasmodium falciparum merozoite protein-142
01/16/2003CA2455490A1 Delivery of dsrna to arthropods
01/16/2003CA2453207A1 Method for isolation of independent, parallel chemical micro-reactions using a porous filter
01/16/2003CA2453176A1 Eubacterial host cells devoid of n-terminal formylation and said host cells being useful for the production of proteins and peptides
01/16/2003CA2453173A1 Mycobacterial antigens expressed during latency
01/16/2003CA2453100A1 Novel human hepatoma lines, methods for obtaining same and uses thereof
01/16/2003CA2453098A1 Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
01/16/2003CA2453075A1 Drug metabolizing enzymes
01/16/2003CA2453068A1 Mesenchymal cells and osteoblasts from human embryonic stem cell
01/16/2003CA2453062A1 Group b streptococcus bvh-a5 antigens and corresponding dna fragments
01/16/2003CA2453042A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells
01/16/2003CA2452980A1 Methods of administering vectors to synaptically connected neurons
01/16/2003CA2452849A1 Method for monitoring and modulating protein folding
01/16/2003CA2452695A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis
01/16/2003CA2452651A1 Use of the cd24 marker gene for the selection of keratinocyte stem cells transformed by exogenous sequences
01/16/2003CA2452628A1 Methylation of histone h4 at arginine 3
01/16/2003CA2452501A1 Secreted proteins
01/16/2003CA2452458A1 Nuclease resistant chimeric oligonucleotides
01/16/2003CA2452399A1 A process for preparing nicotinamide adenine dinucleotide phosphate (nadp)
01/16/2003CA2452396A1 Method of producing template dna and method of producing protein in cell-free protein synthesis system using the same
01/16/2003CA2452359A1 Expression vectors encoding bacteriophage signal peptides
01/16/2003CA2452315A1 Expression of functional human olfactory cyclic nucleotide gated (cng) channel in recombinant host cells and use thereof in cell based assays to identify smell modulators
01/16/2003CA2452310A1 Methods of modulating pharmacokinetics of oligonucleotides
01/16/2003CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
01/16/2003CA2452119A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
01/16/2003CA2451741A1 Peyers's patch and/or m-celle targeting ligands
01/16/2003CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine
01/16/2003CA2451492A1 Recombination systems and a method for removing nucleic acid sequences from the genome of eukaryotic organisms
01/16/2003CA2451395A1 Novel pgc-1 isoforms and uses therefor
01/16/2003CA2451374A1 Aggrecanase molecules
01/16/2003CA2451087A1 Use of histamine receptor h3 gene in controlling body weight or food intake
01/16/2003CA2451055A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours
01/16/2003CA2450867A1 Method of modifying enzyme and oxidoreductase variant
01/16/2003CA2450502A1 Epf receptor assays, compounds and therapeutic compositions